ESMO 2019: Adding Veliparib to Front-Line Treatment of High-Grade Serous Carcinoma
Posted: Tuesday, October 8, 2019
Integrating the PARP inhibitor veliparib with front-line carboplatin and paclitaxel and continued as maintenance monotherapy significantly improved progression-free survival among women with high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin, according to a VELIA/GOG-3005 trial presented at the European Society for Medical Oncology (ESMO) Congress 2019 in Barcelona (Abstract LBA3). Robert L. Coleman, MD, of The University of Texas MD Anderson Cancer Center, and colleagues considered BRCA mutation and homologous recombination deficiency (HRD) status among the patient population and observed toxicities consistent with the known veliparib safety profile. These results were also simultaneously published in The New England Journal of Medicine.
This phase III multinational trial enrolled 1,140 previously untreated patients with high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin. Patients received carboplatin and paclitaxel following cytoreduction. Of these patients, 26% had BRCA-mutated disease, and 55% had HRD. Patients were randomly assigned to receive veliparib or a placebo during chemotherapy and as maintenance treatment. Dose intensities were similar between the treatment arms.
Progression-free survival improved among patients treated with veliparib regardless of selection according to BRCA mutations or HRD status (P < .001); specifically, in those with HRD, progression-free survival was 31.9 months with veliparib and 17.3 months without it. Grade 3 and 4 adverse events were similar among patients in the veliparib/chemotherapy and placebo/chemotherapy groups, with the exception of thrombocytopenia (27% vs. 8%, respectively). During maintenance therapy, grade 3 or 4 adverse events were higher among patients treated with veliparib (45% vs. 32%), however, serious adverse events were similar between both arms (17% vs. 19%).
Disclosure: The study authors’ disclosure information may be found at cslide.ctimeetingtech.com.
